Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

You may also be interested in...



Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute

The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.

Medivation Battles UCLA Over Rights To Prostate Cancer Compound

UCLA researchers secretly developed a compound almost identical to Medivation’s MDV3100 (enzalutamide), a breach of contract suit claims. The company expects to launch MDV3100 later this year.

MedImmune’s Alzheimer’s Antibody Partnership With Axerion Showcases Virtual Neuroscience R&D Operation

The two companies will work together to optimize and develop preclinical antibodies targeted at blocking amyloid-beta oligomer binding to cellular prion protein.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel